KalVista Pharmaceuticals Inc. (NASDAQ: KALV) reported $49.1 million in global net product revenue from EKTERLY during the eight months ended December 31, 2025, according to the company's transition period financial results.

The company received 1,702 patient start forms in the US from launch through February, representing approximately 20% of the US patient population. EKTERLY activated 724 unique prescribers during this period. The majority of fourth quarter 2025 revenue came from patient refills of the hereditary angioedema treatment.

EKTERLY launched in Japan through partner Kaken Pharmaceutical Co., Ltd. and was listed on the National Health Insurance drug reimbursement price list. The oral on-demand therapy is the first of its kind available in Japan.

KalVista completed enrollment in its Phase 3 KONFIDENT-KID trial of sebetralstat in pediatric HAE patients aged 2 to 11 years, finishing one year ahead of schedule. The company expects to file a US new drug application in the third quarter of 2026 with a launch anticipated in 2027.

For the eight-month transition period, the company reported cost of revenue of $3.1 million. Research and development expenses decreased to $33.4 million from $52.2 million in the prior year period. Selling, general and administrative expenses increased to $124.7 million from $64.9 million, primarily due to commercialization expenses related to EKTERLY.

The company recorded a net loss of $109.5 million, or $2.03 per share, compared to a net loss of $110.5 million, or $2.30 per share, in the prior year period. KalVista had cash, cash equivalents and marketable securities of approximately $300.2 million as of December 31, 2025.

The company changed its fiscal year end from April 30 to December 31, resulting in the eight-month transition period from May 1, 2025 to December 31, 2025.